Plasmodium folate metabolic pathway (PFMP)

The Plasmodium folate metabolic pathway is a vital biochemical network responsible for the de novo synthesis and salvage of folate cofactors in malaria-causing parasites. These cofactors, particularly tetrahydrofolate, are indispensable for the synthesis of pyrimidines and certain amino acids required for DNA replication and parasite proliferation [1]. Unlike their human hosts, who acquire folate through diet, Plasmodium parasites must synthesize it or use specialized salvage mechanisms, making this pathway an ideal target for selective chemotherapy [2]. The pathway is primarily targeted by antifolate drugs that inhibit two key enzymes: dihydropteroate synthase (DHPS) and dihydrofolate reductase-thymidylate synthase (DHFR-TS) [4]. Drugs such as sulfadoxine and pyrimethamine act as competitive inhibitors, effectively starving the parasite of the nucleotides needed for survival [5]. However, the clinical utility of these drugs is increasingly threatened by the widespread development of point mutations in the parasite's dhfr and dhps genes, which reduce drug binding affinity and lead to treatment failure [2]. Continued research into this pathway is essential for the development of next-generation inhibitors that can overcome existing resistance mechanisms and provide effective malaria treatment.

Other names

Plasmodium folate biosynthesis pathwayFolate metabolism in malaria parasitesDe novo folate synthesis pathway in Plasmodium

Inhibition of key enzymes within the pathway, specifically dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR), which prevents the synthesis of tetrahydrofolate, a necessary cofactor for DNA synthesis [1][2].